Drug Approval | June 13, 2026
UK approves Wegovy pill in major shift in obesity treatment options
Approval is based on results from the phase 3 OASIS 4 clinical trial
Approval is based on results from the phase 3 OASIS 4 clinical trial
Funding will support the expansion of Remidio’s Oculomics platform to identify early signs of pre-eclampsia, anemia and gestational diabetes through retinal imaging, targeting underserved communities
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Community healthcare initiatives reach a milestone year, with services spanning 90 districts, 22 states, and over 70 lakh cumulative beneficiaries since 2006
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
Subscribe To Our Newsletter & Stay Updated
